Evidence map›Paper›PMID 36109550›Full record

ArticleScientific reports2022

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Xia Cao, Junki Maruyama, Heyue Zhou, Yanwen Fu, Lisa Kerwin, Colin Powers, Rachel A Sattler, John T Manning, Alok Singh, Reyna Lim and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 2 institutions in 1 country.

Xia CaoSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Junki MaruyamaGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Heyue ZhouSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Yanwen FuSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Lisa KerwinSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Colin PowersSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Rachel A SattlerGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
John T ManningGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Alok SinghSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Reyna LimSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Laura D HealySorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Sachi JohnsonSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Elizabeth Paz CabralSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Donghui LiSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Lucy LuSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Arthur LedesmaSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Daniel LeeSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Susan RichardsSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Laura Rivero-NavaSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Yan LiSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Weiqun ShenSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Karen StegmanSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Benjamin BlairSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Shinji UrataGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Magumi Kishimoto-UrataGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Jamie KoSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Na DuSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Kyndal MoraisSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Kate LawrenceSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Ianne RiveraSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Chin-I PaiSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Damien BressonSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Mark BrunswickSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Yanliang ZhangSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Henry JiSorrento Therapeutics, Inc., San Diego, CA, 92121, USA. hji@sorrentotherapeutics.com.
Slobodan PaesslerGalveston National Laboratory, Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA. SLPAESSL@utmb.edu.
Robert D AllenSorrento Therapeutics, Inc., San Diego, CA, 92121, USA.
Sorrento Therapeutics (United States) · USThe University of Texas Medical Branch at Galveston · US

Funding

Viral factors responsible for Lassa virus pathogenicityK99AI156012 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MARUYAMA, JUNKI · 2021 to 2022
$177k
NIAID NIH HHS K99 AI156012
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

Indexed as

COVID-19AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCricetinaeHumansMesocricetusNeutralization TestsSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralSTI-2020

Identifiers

PMID36109550
PMCPMC9476467
OpenAlexW4295949456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.